The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Trop. Dis
Sec. Vaccines for Tropical Diseases
Volume 5 - 2024 |
doi: 10.3389/fitd.2024.1441973
This article is part of the Research Topic One Health and Preparedness for Disease X in the Tropics: Spillover Prevention, Surveillance, Vaccines and Drugs View all 7 articles
Dengue Vaccine Endgame: Why Has the Global Response to Exponential Demand in the Tropics Been So Slow?
Provisionally accepted- 1 Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
- 2 Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil
- 3 Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- 4 School of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Paraná, Brazil
- 5 National Institute of Industrial Property, Rio de Janeiro, Brazil
- 6 Bio-Manguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, Paraná, Brazil
Introduction: There has been a dramatic global surge in Dengue Fever (DF) in recent years, with projected 100-400 million cases annually and large outbreaks expected every 3-4 years. This concerning scenario is in sharp contrast to the very low availability of Dengue vaccines to meet this spiraling demand, affecting particularly developing countries in Latin American and Africa. In our study we aim to identify current vaccine development constraints, from a technological perspective, based on clinical trials and patent landscape data. Methods: This study was conducted in a two-step methodology: first, candidates and launched products and methods used in development or as part of Dengue Fever (DF) vaccines have been identified from the Cortellis Drug Discovery Intelligence (CDDI) platform. Second, the Derwent Innovation database was used to retrieve patent documents related to Dengue vaccines. Data collected in the period 2014-2024 (to identify the candidate and or launched vaccines) and 2018-2022 (to identify patent documents) with claims involving applications to Dengue vaccine development. We presented these descriptive data in the following format: quantitative and qualitative assessment describing the vaccine development scenario and the claimed vaccine technologies. Results: Our study indicated that 65% of Dengue vaccines are still in Phase 1 of development. The few current dengue vaccines that have reached phase 3 (1) and launched (2) have shown limited levels of individual protection for one or more dengue serotypes and an anemic pipeline of the next generation of more effective tetravalent dengue vaccines. Although the intelligent use of multiple dengue vaccine formulations in immunizations campaigns can result in an effective protection against all serotypes at population level, its implementation is complex and challenging. The results of our study evidence thus a worrisome global situation regarding the development of new Dengue vaccine candidates. Conclusion: To reverse this scenario, there is an urgent need of to implement new knowledge governance approaches and business models to stimulate an exponential increase in global vaccine development funding for dengue and several other vaccines.
Keywords: Dengue vaccine, Immunotherapy, innovation, platforms, clinical trials, Patents
Received: 31 May 2024; Accepted: 09 Aug 2024.
Copyright: © 2024 Possas, Marques, Oliveira, Schumacher, Antunes and Homma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Cristina Possas, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Ernesto T. Marques, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.